Skip to main content

Table 2 Results from drug screening and referenced achievable plasma concentrations

From: A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies

Drug IC50 (μM) Achievable concentrations in plasma (based on the literature)
BD DH82 [plasma] (μM) Species Dose Effect Ref.
Dasatinib 0.01 0.009 0.3 dog 3 mg/kg NOAEL [72]
Erlotinib 3.2 4.3 6.9 dog 150 mg TD [73]
Gefitinib 30.7 46.4 2.6 dog 100 mg/kg NOAEL [74]
Imatinib 34 39.2 0.66 dog 10 mg/kg NOAEL [75]
Masitinib 15.7 39.1 1.5 dog 10 mg/kg TD [76]
Nilotinib 29.9 26.2 1.4 dog 20 mg/kg NOAEL [77]
Toceranib 1.9 1.7 0.1 dog 3.25 mg/kg TD [78]
Sorafenib 36.3 13.6 13.3 human 400 mg TD [79]
Sunitinib 4.5 17.9 0.12 human 50 mg TD [80]
Tozasertib 7.7 1.3 0.27 human 8 mg/m2 TD [81]
CCNU 105 139.5 4.2 human 130 mg/m2 TD [69]
Cladribine a 64 222 0.028 human 0.09 mg/kg TD [82]
Doxorubicin a 0.09 0.41 1.13 dog 30 mg/m2 TD [83]
  1. a Compounds administered intravenously
  2. NOAEL: no-observed-adverse-effect level
  3. TD: therapeutic dosage